ST Pharm Co.,Ltd. (KOSDAQ:237690)

South Korea flag South Korea · Delayed Price · Currency is KRW
152,300
+5,200 (3.54%)
Feb 27, 2026, 3:30 PM KST
85.73%
Market Cap 3.16T
Revenue (ttm) 318.32B
Net Income (ttm) 36.89B
Shares Out 20.78M
EPS (ttm) 1,795.21
PE Ratio 84.84
Forward PE 49.69
Dividend 500.00 (0.33%)
Ex-Dividend Date Mar 30, 2026
Volume 241,478
Average Volume 221,212
Open 144,500
Previous Close 147,100
Day's Range 144,300 - 157,500
52-Week Range 66,600 - 166,300
Beta 0.34
RSI 57.16
Earnings Date Feb 5, 2026

About ST Pharm

ST Pharm Co.,Ltd., provides manufacturing services for active pharmaceutical ingredient and intermediate. The company offers small molecule and generics, an ingredient for treating viral infections; oligonucleotide based products, such as siRNA/microRNA, antisense, aptamer, decoys, and other novel oligos; monomer; and mRNA for vaccines and therapeutics. It also offers pre-clinical and bioanalytical research and development solutions. The company was formerly known as Samchully Pharmaceutical Company., Ltd. ST Pharm Co. Ltd. was founded in 1983 ... [Read more]

Industry Medical - Pharmaceuticals
Sector Healthcare
Founded 1983
Employees 655
Stock Exchange KOSDAQ
Ticker Symbol 237690
Full Company Profile

Financial Performance

In 2024, ST Pharm's revenue was 273.75 billion, a decrease of -3.94% compared to the previous year's 284.99 billion. Earnings were 34.71 billion, an increase of 77.27%.

Financial Statements

News

There is no news available yet.